(Albany, USA) DelveInsight’s, “Interstitial Cystitis Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Interstitial Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
For Interstitial Cystitis Emerging drugs, the Interstitial Cystitis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Acute Pyelonephritis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Request for Sample Pages: Interstitial Cystitis Pipeline Analysis
Some of the key highlights from the Interstitial Cystitis Pipeline report:
The Interstitial Cystitis Pipeline report offers a rich analysis of 8+ key players and 10+ key therapies.
Interstitial Cystitis pipeline comprises therapies in different stages of the clinical phase such as include Certolizumab pegol, SI-722, IW-3300, and many others expected to enter the Interstitial Cystitis market in the coming years.
Key companies strengthening the Interstitial Cystitis Pipeline are Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Addex Therapeutics, Seikagaku Corporation, UCB, Alivio Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, and many others.
In July 2024, Ironwood Pharmaceuticals, Inc announced results of a Phase 2 Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate the Efficacy, Safety, and Tolerability of 2 Dose Levels of IW-3300 Administered Rectally for 12 Weeks to Treat Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
In June 2024, Imbrium Therapeutics announced results of a Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome
In May 2024, Vaneltix Pharma, Inc announced results of a Phase 2b, Open Label, Single-Arm, Multi-Center, Multiple Dose, 14-Day Study to Evaluate the Safety, Efficacy, and Frequency of Intravesical Administration of VNX001 in Acute Treatment of Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity
Some of the key Interstitial Cystitis companies working in the market are:
Merck & Co
Teva Pharmaceutical Industries
Integrative Therapeutics, Inc.
Lipella Pharmaceuticals, Inc.
Addex Therapeutics
Seikagaku Corporation
UCB
Alivio Therapeutics
Imbrium Therapeutics
Ironwood Pharmaceuticals, And Many Others.
Learn more about the emerging Interstitial Cystitis pipeline therapies @ Interstitial Cystitis Treatment Market
Interstitial cystitis Overview:
Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic, or long-lasting, condition that causes painful urinary symptoms. Symptoms of IC may be different from person to person. For example, some people feel mild discomfort, pressure, or tenderness in the pelvic area. Other people may have intense pain in the bladder or struggle with urinary urgency, the sudden need to urinate, or frequency, the need to urinate more often. IC can occur at any age, including during childhood, but is most common in adult women and men. About twice as many women are affected as men.1 However, more men may struggle with IC than researchers originally thought. Some research suggests that women are more likely to develop IC if they have a history of being physically traumatized
Interstitial Cystitis Emerging Drugs
Certolizumab pegol: UCB
Certolizumab pegol (Cimzia) developed by UCB, Belgium is a recombinant, humanized F(ab)’ fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It is in phase 3 stage of development for the treatment of Interstitial cystitis.
SI-722: Seikagaku Corporation
SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku’s proprietary glycosaminoglycan modification technology and drug delivery systems (DDS). SI-722 injected into the bladder is thought to demonstrate long-lasting improvement in the conditions of frequent urination and bladder pain by releasing a steroid with an anti-inflammatory effect. SI-722 has completed a Phase I clinical study in the U.S. In November 2019, it is starting a Phase I/II clinical study. This clinical study will evaluate the drug for safety, tolerability, and pharamcokinetics, and will conduct an exploratory evaluation of its effectiveness.
Request a sample and discover the recent advances in Interstitial Cystitis treatment drugs @ Interstitial Cystitis Therapeutic Assessment
Interstitial Cystitis Analytical Perspective by DelveInsight
In-depth Interstitial Cystitis Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
Interstitial Cystitis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.
Request a Interstitial Cystitis pipeline report sample @ Interstitial Cystitis Drugs and Therapies
Scope of the Interstitial Cystitis pipeline report
The Interstitial Cystitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Interstitial Cystitis across the complete product development cycle, including all clinical and nonclinical stages.
It comprises of detailed profiles of Interstitial Cystitis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
Detailed Interstitial Cystitis research and development progress and trial details, results wherever available, are also included in the pipeline study.
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Interstitial Cystitis.
Dive deep into rich insights for new drugs for Interstitial Cystitis treatment, visit @ Interstitial Cystitis Clinical Trials and FDA Approvals
Table of Content:
Introduction
Executive Summary
Interstitial Cystitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Interstitial Cystitis Pipeline Therapeutics
Comparative Analysis
Interstitial Cystitis Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Certolizumab pegol: UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Interstitial Cystitis Preclinical and Discovery Stage Products
Comparative Analysis
LYT 503: PureTech Health
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Interstitial Cystitis Products
Comparative Analysis
Interstitial Cystitis Companies
Interstitial Cystitis Key Products
Interstitial Cystitis Unmet Needs
Interstitial Cystitis Market Drivers and Barriers
Interstitial Cystitis Future Perspectives and Conclusion
Interstitial Cystitis Analyst Views
Interstitial Cystitis Companies
Appendix
About DelveInsight
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage
